Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedSci Healthcare HoldingsHKSE:02415 79 EBITDA Margin % is 5.30% as of Dec. 2025, which is 52% below its 10-year median of 10.99. GuruFocus rates HKSE:02415 with a GF Score™ of 79/100 and a GF Value™ of HK$1.44 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 663 Healthcare Providers & Services companies, MedSci Healthcare Holdings ranks worse than 52.64% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
MedSci Healthcare Holdings EBITDA Margin % Related Terms
MedSci Healthcare Holdings EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02415 vs VEEV, BTSG, HQY: EBITDA Margin % Comparison
For the Health Information Services subindustry, MedSci Healthcare Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MedSci Healthcare Holdings EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MedSci Healthcare Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where MedSci Healthcare Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MedSci Healthcare Holdings (HKSE:02415) has a EBITDA Margin % of 5.30% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on MedSci Healthcare Holdings and its competitors. This is 52% below median its historical median of 10.99. According to the industry distribution chart, MedSci Healthcare Holdings ranks #349 out of 663 companies in the Healthcare Providers & Services industry, placing it in the top 52.6%.
Is MedSci Healthcare Holdings' EBITDA Margin % too high?
MedSci Healthcare Holdings' current EBITDA Margin % of 5.30% is 52% below median its 10-year median of 10.99. The Healthcare Providers & Services industry median EBITDA Margin % is 10.19. MedSci Healthcare Holdings' value of 5.30% is 48% below this industry median. Based on the distribution chart, MedSci Healthcare Holdings ranks #349 out of 663 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, MedSci Healthcare Holdings has a GF Score™ of 79/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MedSci Healthcare Holdings' EBITDA Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, MedSci Healthcare Holdings ranks #349 out of 663 companies for EBITDA Margin %. This places MedSci Healthcare Holdings in the lower half of its industry. The industry median EBITDA Margin % is 10.19. MedSci Healthcare Holdings' value of 5.30% is 48% below this benchmark. While the company's 10-year median is 10.99 vs. the industry median of 10.19, MedSci Healthcare Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.19, based on 663 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MedSci Healthcare Holdings's current EBITDA Margin % of 5.30% is 48% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on MedSci Healthcare Holdings and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MedSci Healthcare Holdings's current EBITDA Margin % is 5.30%, which is 52% below median its own 10-year median of 10.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedSci Healthcare Holdings stock overvalued right now?
Based on GuruFocus' analysis, MedSci Healthcare Holdings (HKSE:02415) is currently considered Possible Value Trap. The stock's GF Value™ is HK$1.44, compared to a current price of HK$0.73 — trading 49.3% below its estimated fair value. The current EBITDA Margin % is 5.30%, which is 52% below median its 10-year median of 10.99 and 48% below the Healthcare Providers & Services industry median of 10.19. MedSci Healthcare Holdings' overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For MedSci Healthcare Holdings (HKSE:02415), the current EBITDA Margin % is 5.30% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MedSci Healthcare Holdings (HKSE:02415) Overvalued in 2026?
Based on GuruFocus' analysis, MedSci Healthcare Holdings stock appears to be undervalued.
The current stock price of HK$0.73 is trading 49.3% below its estimated GF Value™ of HK$1.44.
GuruFocus considers MedSci Healthcare Holdings to be Possible Value Trap.
Key valuation signals for HKSE:02415:
EBITDA Margin %: 5.30% (52% below median its 10-year median of 10.99)
GF Value™: HK$1.44 vs. price of HK$0.73 (49.3% below fair value)
Industry Position: 48% below the Healthcare Providers & Services median (#349 of 663)
No single metric tells the full story. See the HKSE:02415 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MedSci Healthcare Holdings Ltd is an investment holding company. It operates online professional physician platforms in China. The principal activities of the company are the provision of physician platform solutions, precision omni-channel marketing solutions, and real-world study solutions in the People's Republic of China.
79GF Score
Get the complete analysis for HKSE:02415
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02415 has been successfully added to your 
